Inventiva S.A. (IVA)

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

undefined

undefined%

At close: undefined

2.45

1.24%

After-hours Dec 13, 2024, 02:47 PM EST

Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.

Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.

The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease.

In addition, it has a pipeline of earlier stage programs in oncology and other diseases.

The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis.

Inventiva S.A. was founded in 2011 and is based in Daix, France.

Inventiva S.A.

Country	FR
IPO Date	Jul 10, 2020
Industry	Biotechnology
Sector	Healthcare
Employees	123
CEO	Frederic Cren

Contact Details

Address: 50 rue de Dijon Daix, FR
Website	https://www.inventivapharma.com

Stock Details

Ticker Symbol	IVA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001756594
CUSIP Number	46124U107
ISIN Number	US46124U1079
Employer ID	00-0000000
SIC Code	2834

Key Executives

Name	Position
Dr. Pierre Broqua Ph.D.	Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer & Director
Frederic Cren	Co-Founder, Chief Executive Officer & Chairman
Alice Roudot-Ketelers Pharm.D.	Chief Operating Officer
Jean Volatier	Deputy GM & Chief Financial Officer
Dr. Kristina Meyer Ph.D.	Executive Vice President and Business Development & Alliance Management
Dr. Michael Cooreman	Chief Medical Officer
Eric Duranson L.L.M.	General Counsel
Nathalie Harroy	Head of Human Resources
Pascaline Clerc Ph.D.	Executive Vice President of Strategy & Corporate Affairs

Latest SEC Filings

Date	Type	Title
Dec 12, 2024	6-K	Filing
Nov 26, 2024	6-K	Filing
Nov 21, 2024	6-K	Filing
Nov 20, 2024	6-K	Filing
Nov 20, 2024	6-K	Filing
Nov 15, 2024	6-K	Filing
Nov 14, 2024	6-K	Filing
Nov 13, 2024	SCHEDULE 13G/A	[Amend] Filing
Nov 04, 2024	6-K	Filing
Oct 30, 2024	6-K	Filing

View All SEC Filings